Status:
COMPLETED
An Audit of Patients With Crohn's Disease Treated With Infliximab (P06066)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
Crohn's Disease
Eligibility:
All Genders
18+ years
Brief Summary
The aim of this study is to quantify how infliximab therapy is being used in the UK and the consequent impact on health care resources, which will help to inform budget holders and payers on the costs...
Detailed Description
All interested hospital physicians across the UK who prescribe infliximab as part of their treatment of Crohn's Disease patients. will be included. It is assumed that the physician population will con...
Eligibility Criteria
Inclusion
- Diagnosis of Crohn's Disease.
- Over the age of 18 years.
- Must have received the first infusion of infliximab on or after 1st January 2003 (when the maintenance therapy license was granted).
- Must have received at least one infusion of infliximab.
- A minimum of 12 months data prior to, and 24 months data post infliximab exposure should be available in the medical records.
- Must have been under the care of the participating center for the entirety of the study period.
Exclusion
- Should not have been involved in any clinical trial during the observational period (ie, a minimum of 12 months before and 24 months after first receiving infliximab).
- Should not have received any biologic therapy prior to infliximab.
Key Trial Info
Start Date :
February 1 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2010
Estimated Enrollment :
380 Patients enrolled
Trial Details
Trial ID
NCT00988832
Start Date
February 1 2010
End Date
December 1 2010
Last Update
September 2 2015
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.